NASDAQ:BIOC - Biocept, Inc.
$1.02
 $0.00
0.00%
4:00PM EDT
2019-04-18
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BIOC     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 00   203. 85   241. 91  
42 stocks rank:  4. 39 K 1. 44 K 1. 05 K
# analyst opinions:  3. 00   14. 51   13. 97  
mean recommendation:  2. 00   2. 09   2. 01  

quick ratio:  1. 08   5. 27   1. 81  
current ratio:  1. 30   5. 62   2. 25  

target price low:  3. 00   84. 80   115. 21  
target price avg:  1. 41   111. 51   137. 51  
target price high:  0. 70   135. 81   157. 84  
1-yr high:  8. 10   114. 23   138. 78  
last close:  1. 02   87. 66   116. 69  
50-day avg:  1. 10   95. 54   123. 44  
200-day avg:  2. 32   94. 25   121. 11  
1-yr low:  0. 69   72. 78   98. 34  
volume:  660. 67 K 4. 11 M 8. 07 M
50-day avg volume:  2. 49 M 2. 76 M 5. 02 M
200-day avg volume:  1. 49 M 2. 92 M 4. 59 M

1-day return:  0. 00 % -0. 41 % 0. 07 %
this week return:  -2. 86 % -5. 74 % -4. 11 %
12-wk return:  -47. 42 % 1. 61 % -0. 05 %
52-wk return:  -85. 83 % 3. 12 % 8. 78 %

enterprise value (EV):  17. 40 M 48. 94 B 114. 64 B
market cap:  19. 24 M 43. 07 B 104. 73 B
EBITDA:  -23. 46 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 74   4. 22   12. 73  
enterprise/revenue (EV/R):  5. 35   63. 17   12. 84  
total revenue:  3. 25 M 10. 62 B 38. 47 B
total debt:  1. 63 M 12. 24 B 16. 73 B
debt/equity:  53. 46   46. 71   89. 62  
net income (common):  -25. 21 M 2. 20 B 4. 20 B

shares outstanding:  18. 87 M 571. 70 M 1. 24 B
shares:  18. 80 M 571. 81 M 1. 23 B
shares short:  1. 13 M 10. 17 M 13. 00 M
shares short prior month:  504. 60 K 9. 54 M 17. 33 M
short ratio:  0. 31   5. 41   3. 28  
short % of float:  50. 47 % 5. 45 % 2. 38 %
total cash/share:  0. 18   11. 14   9. 33  
total cash:  3. 42 M 6. 71 B 7. 15 B
free cash flow:  -13. 61 M 3. 58 B 2. 96 B
operating cash flow:  -22. 36 M 4. 15 B 4. 30 B

book value:  0. 66   12. 78   26. 92  
price/book:  1. 55   3. 06   -1. 74  
operating margins:  -746. 35 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  -209. 26 % 37. 08 % 55. 70 %

1-yr max volatility:  139. 13 % --- ---
1-yr mean volatility:  0. 01 % 0. 03 % 0. 04 %

1-yr EPS:  -9. 01   2. 40   4. 10  
forward EPS:  -0. 68   3. 97   7. 13  
P/E:  -0. 11   13. 63   22. 72  
forward P/E:  -1. 50   -15. 95   13. 99  
PE/G:  0. 01   -1. 65   -1. 32  
growth:  -13. 60 % 127. 12 % 29. 61 %
earnings high:  -0. 00   1. 00   1. 66  
earnings avg:  -0. 00   0. 77   1. 53  
earnings low:  -0. 00   0. 50   1. 39  
revenue high:  1. 43 M 2. 68 B 10. 78 B
revenue avg:  1. 43 M 2. 59 B 10. 57 B
revenue low:  1. 43 M 2. 49 B 10. 36 B
return on assets:  -188. 00 % -2. 75 % 4. 55 %
return on equity:  -1132. 71 % -18. 45 % 5. 46 %
revenue growth:  -13. 60 % 92. 86 % 18. 96 %
revenue/share:  1. 16   13. 29   55. 46  

beta (1yr vs S&P500):  -0. 93   1. 25   0. 93  
sharpe (1yr):  0. 02   0. 37   0. 70  

held % insiders:  0. 23 % 6. 39 % 3. 38 %
held % institutions:  13. 41 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : BIOC
.        + 0 =             0 :: INITIAL WEIGHT
.   + 35.995 =        35.995 :: spline projection addition
.    x 1.431 =        51.523 :: industry recommendation factor
.    x 2.122 =       109.308 :: symbol recommendation factor
.    x 1.085 =       118.568 :: EV/R factor
.    x 0.981 =       116.339 :: return on assets factor
.    x 0.887 =       103.161 :: return on equity factor
.    x 0.999 =       103.021 :: revenue growth factor
.    x 2.232 =       229.928 :: current ratio factor
.    x 2.075 =       477.008 :: quick ratio factor
.    x 1.918 =       914.932 :: short ratio factor
.    x 2.016 =      1844.068 :: price-to-book factor
.    x 1.362 =      2511.987 :: debt-to-equity factor
.    x 2.176 =       5465.15 :: P/E weight
.    x 2.209 =     12072.293 :: PE/G factor
.    x 1.405 =      16962.06 :: beta factor
.    x 0.015 =       261.914 :: sharpe factor
.    x 2.643 =       692.123 :: target low factor
.    x 1.205 =       834.218 :: target mean factor
.    x 0.944 =       787.492 :: target high factor
.     x 1.31 =      1031.527 :: industry 2-weeks return factor
.     x 0.63 =       650.204 :: overall "drift" factor
.    x 0.348 =       226.158 :: largest single-day jump factor
.    x 0.062 =        13.995 :: low price factor
.      x 1.0 =        13.993 :: factor hist industry gain for week 16
.   cubeRoot =          2.41 :: reduced to standardize
.   - 32.307 =         0.001 :: add/subtract for performance
.                      0.001 :: FINAL WEIGHT for NASDAQ:BIOC


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org